Spiker 1985.
Study characteristics | ||
Methods | Randomised, double‐blind comparison Random assignment procedure described in part Blinding adequately described | |
Participants | SADS and RDC criteria for major depressive disorder, primary subtype, and psychotic subtype (only with delusions); bipolar participants included Severity rating ≥ 4 on 6‐point scale in the SADS that rates severity of delusion HRSD‐17 > 14 Inpatients No data about prior treatment for current episode | |
Interventions | 3 groups: perphenazine vs amitriptyline vs amitriptyline + perphenazine Doses: perphenazine mean 50 mg vs amitriptyline mean 218 mg vs amitriptyline mean 170 mg + perphenazine mean 54 mg Blood levels: perphenazine 19 to 113 ng/mL vs amitriptyline (+ nortriptyline) 130 to 500 ng/mL vs amitriptyline 157 to 690 ng/mL + perphenazine 18 to 128 ng/mL 7 days drug free Treatment period: 4 weeks Additional medication: benztropine mesylate 4 mg | |
Outcomes | Dichotomous data: study author defined: response is HRSD‐17 < 7 and delusional rating score = 1 (6‐point scale in the SADS). No remission data (definition of response is definition of remission) Continuous data: symptom reduction: no ITT data; global response: no ITT data; QOL: no data Overall dropout rate: yes Dropout due to adverse effects: amitriptyline + perphenazine 2/22, perphenazine 1/17 Mortality rate: 0 | |
Notes | Only participants with delusions 7 drop out in ITT (in the original data, dropouts are excluded from the analysis); response data ITT 3/17 (original 3/16); 7/19 (7/17); 14/22 (14/18) 9/58 = 15.5% bipolar participants in analysis. Because of lack of data, we were not able to exclude these bipolar participants from the analysis | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | As reported: "the hospital pharmacist assigned patients randomly" |
Allocation concealment (selection bias) | Low risk | Probably yes: "the hospital pharmacist assigned patients randomly" |
Blinding (performance bias and detection bias) of participants | Low risk | As reported: "the hospital pharmacist assigned patients randomly. All tablets looked identical" "All raters and floor staff and the patient were blind to the patient's drug treatment and the plasma‐level data" |
Blinding (performance bias and detection bias) of personnel | Low risk | As reported: "the hospital pharmacist assigned patients randomly. All tablets looked identical" "All raters and floor staff and the patient were blind to the patient's drug treatment and the plasma‐level data" |
Blinding (performance bias and detection bias) of outcome assessors | Low risk | As reported: "the hospital pharmacist assigned patients randomly. All tablets looked identical" "All raters and floor staff and the patient were blind to the patient's drug treatment and the plasma‐level data" |
Incomplete outcome data (attrition bias) All outcomes | Low risk | None |
Selective reporting (reporting bias) | Unclear risk | No protocol available. Generally accepted outcomes have been used |
Other bias | Unclear risk | Only participants with delusions are included 9/58 = 15.5% bipolar participants in analysis. Because of lack of data, we were not able to exclude these bipolar participants from the analysis We re‐analysed the data to ITT |